Sector News

Stryker CEO says he remains focused on acquisitions

January 29, 2015
Life sciences
(Reuters) – The chief executive officer of U.S. medical device maker Stryker Corp (SYK.N), recently rumored to have been preparing a bid for British rival Smith & Nephew Plc (SN.L), said on Tuesday that acquisitions are his top priority for spending cash, but he gave no hint that any sort of deal was imminent.
 
The timing of acquisitions is unpredictable, Stryker Chief Executive Officer Kevin Lobo said on the company’s fourth-quarter earnings conference call.
 
“Right now we are pursuing the acquisition deal flow, and we’ll see what happens,” Lobo said. “We do plan to put our money to work.”Rumors that Stryker could bid soon for fellow orthopedic implant maker Smith & Nephew, frequently named as a possible takeover candidate, surfaced late last month.
 
Smith & Nephew CEO Olivier Bohuon, speaking earlier this month at an investor conference, said the company had not decided to follow other medical device makers that are bulking up through mergers.
 
Years of slow growth and persistent price erosion have prompted some large mergers in the orthopedic implant sector, with Johnson & Johnson (JNJ.N) buying Swiss device maker Synthes for about $21 billion in 2012, and Zimmer Holdings Inc (ZMH.N) in the process of acquiring privately held Biomet for $13.4 billion.
 
Stryker itself has been active in acquiring smaller companies, including its $1.65 billion deal for Mako Surgical Corp in 2013.
 
The Kalamazoo, Michigan-based maker of artificial hips and knees and other hospital supplies said on Tuesday its fourth-quarter net earnings fell 33 percent to $260 million, or 67 cents a share, hurt by charges for product recalls and costs related to opening a regional headquarters in Europe.
 
The company earned $386 million, or $1.01 a share, a year ago. Sales rose 6.1 percent to $2.62 billion in the latest quarter.
 
(Reporting by Susan Kelly in Chicago. Editing by Andre Grenon)

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.